ClearPath Diagnostics Announces New CEO, Jack Finn, and Launches Expanded Growth Strategy

Syracuse, NY (PRWEB) December 03, 2012

ClearPath Diagnostics, an independent, physician-owned anatomic pathology laboratory, has hired Jack Finn as its new CEO. Finn was formerly CEO and president of Centrex Laboratories where he developed the strategy that led the company to be recognized as one of the nations premier regional laboratories.

ClearPath also announced a three-pronged strategy for growth: It has widened its service area throughout New York State and into Pennsylvania, Connecticut, Rhode Island and Massachusetts, expanded its anatomic pathology services to dermatologists, urologists and gastroenterologists, as well as offering a broad menu of laboratory services to hospitals.

When I consider ClearPaths depth, expertise, and excellence of services, and then look at the extraordinary opportunities that we can offer both physicians and hospitals, I expect great things for this companys future, said Finn. To be a part of this plan for growth is really exciting.

Dr. Michael Jozefczyk, a pathologist and ClearPath president said, Hospitals, along with physicians and the patients they serve, are facing challenges as never before in seeking ways to improve patient outcomes at lower system-wide healthcare costs. We are confident ClearPath can offer them exceptional value. Jacks expertise in the hospital-based lab environment, combined with his deep experience and knowledge of physician markets, make him the ideal choice to lead us there.

During his tenure, Finn helped Centrex grow from $ 1 million in sales to almost $ 50 million. Cited internationally for his expertise, Finn is a sought-after speaker on sales, marketing, and hospital outreach programs. He was recognized by the Dark Report as one of the Laboratory Industrys Movers and Shakers. He began his career as a medical technologist.

ClearPath Diagnostics has provided pathology services since 1975. For more information, please visit

Leave a Comment

You must be logged in to post a comment.